Jacob George
Corporate Officer/Principal bij The Hebrew University of Jerusalem
Profiel
Jacob George was the founder of Vascular Biogenics Ltd.
(founded in 2000) and Chemomab Ltd.
(founded in 2011), where he held the titles of Chief Scientific Officer and Director, respectively.
He currently holds the title of Professor-Cardiology at The Hebrew University of Jerusalem.
Dr. George received a doctorate degree from Technion-Israel Institute of Technology.
Actieve functies van Jacob George
| Bedrijven | Functie | Begin |
|---|---|---|
| The Hebrew University of Jerusalem | Corporate Officer/Principal | - |
Eerdere bekende functies van Jacob George
| Bedrijven | Functie | Einde |
|---|---|---|
Chemomab Ltd.
 Chemomab Ltd. BiotechnologyHealth Technology ChemomAb Ltd. develops novel chemokine blocking therapies for inflammatory and fibrotic disorders. It specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The company was founded by Adi Mor and Jacob George in 2011 and is headquartered Tel Aviv, Israel. | Oprichter | - |
| NOTABLE LABS, LTD. | Oprichter | - |
Opleiding van Jacob George
| Technion-Israel Institute of Technology | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Vascular Biogenics Ltd.
 Vascular Biogenics Ltd. BiotechnologyHealth Technology Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel. | Health Technology |
Chemomab Ltd.
Chemomab Ltd. BiotechnologyHealth Technology ChemomAb Ltd. develops novel chemokine blocking therapies for inflammatory and fibrotic disorders. It specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The company was founded by Adi Mor and Jacob George in 2011 and is headquartered Tel Aviv, Israel. | Health Technology |
